Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial

Waijer, SW; Vart, P; Cherney, DZI; Chertow, GM; Jongs, N; Langkilde, AM; Mann, JFE; Mosenzon, O; McMurray, JJV; Rossing, P; Correa-Rotter, R; Stefansson, BV; Toto, RD; Wheeler, DC; Heerspink, HJL

Heerspink, HJL (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.;Heerspink, HJL (通讯作者)，George Inst Global Hlth, Sydney, NSW, Australia.

DIABETOLOGIA, 2022; 65 (7): 1085

Abstract

Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索